ADAM10 expression in gastric adenocarcinoma: Results of a curative gastrectomy cohort

Basit Öğe Kaydı
dc.authoridAlakus, Huseyin/0000-0003-2650-7208
dc.contributor.authorAlakus, Huseyin
dc.contributor.authorKaya, Mustafa
dc.contributor.authorOzer, Hatice
dc.contributor.authorEgilmez, Hatice Reyhan
dc.contributor.authorKaradayi, Kursat
dc.date.accessioned2024-10-26T18:08:08Z
dc.date.available2024-10-26T18:08:08Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjective: Gastric cancer is among the most common human cancers with high mortality rates. ADAM10, a member of the ADAM (a disintegrin and metalloproteinase) family has also been found to be associated with gastric carcinoma and has been suggested as a potential therapeutic target. Here, we investigated the association of ADAM10 expression with prognosis in gastric adenocarcinoma patients that underwent gastric resection with D2 lymph node dissection. Methods: Total 86 consecutive patients that underwent resection for gastric adenocarcinoma were included. Immunohistochemical ADAM10 expression and its association with clinicopathological parameters were analyzed. Univariate and multivariate analyses and survival analyses were performed using SPSS ver.22. Results: High grade tumors, advanced stage tumors and diffuse type tumors showed significantly worse prognosis. A statistically significant association between ADAM10 expression and overall survival (OS) was observed in the univariate analysis, however, this association did not maintain its significance in the multivariate analysis. No statistically significant association was found ADAM-10 expression and clinicopathological parameters. Conclusion: Immunohistochemical ADAM10 expression may be used as a prognostic marker in gastric adenocarcinoma, however, introduction of a standardized immunohistochemical scoring system seems to be necessary for evaluation of ADAM10 staining.
dc.description.sponsorshipCumhuriyet University Research Fund [660]
dc.description.sponsorshipThis study was funded by Cumhuriyet University Research Fund (grant number 660).
dc.identifier.doi10.12669/pjms.37.2.3613
dc.identifier.endpage549
dc.identifier.issn1682-024X
dc.identifier.issue2
dc.identifier.pmid33679947
dc.identifier.scopus2-s2.0-85099531001
dc.identifier.scopusqualityQ3
dc.identifier.startpage543
dc.identifier.urihttps://doi.org/10.12669/pjms.37.2.3613
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29835
dc.identifier.volume37
dc.identifier.wosWOS:000616415500045
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherProfessional Medical Publications
dc.relation.ispartofPakistan Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectADAM10 Protein
dc.subjectNeoplasms
dc.subjectrhoA GTP-Binding Protein
dc.subjectStomach Neoplasms
dc.titleADAM10 expression in gastric adenocarcinoma: Results of a curative gastrectomy cohort
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu